River Cities devised a strategy in 2004 to exploit the challenging, yet high-potential dynamic of the US medical device industry. The firm invests in high-potential medical device companies that create the best patient outcomes with the lowest total cost and serve an aging population seeking to stay active longer. The firm also targets devices that advance minimally invasive procedures in the fields of cardiology, urology, oncology, gynecology, orthopedics, neurosurgery and general surgery – as advanced imaging and robotic applications will have profound effects in creating safer and less traumatic procedures. Target companies develop diagnostic technologies for personalized medicine and point of care applications – as genomic, proteomic and metabolomic discoveries will facilitate the migration from symptom-based diagnostics to early detection, advance disease predisposition screening and the associated precautionary steps.
Click here for a case study on River Cities’ portfolio company Suros.